<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976153</url>
  </required_header>
  <id_info>
    <org_study_id>IC-01-02-5-009</org_study_id>
    <nct_id>NCT04976153</nct_id>
  </id_info>
  <brief_title>Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence</brief_title>
  <acronym>Fidelia</acronym>
  <official_title>Skeletal Muscle-derived Cell Implantation for the Treatment of Fecal Incontinence: a Phase III, Randomized, Controlled, Double Blind, Two Armed Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovacell AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovacell AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is the final assessment of clinical safety and efficacy of&#xD;
      autologous autologous skeletal muscle derived cells for patients with urge fecal incontinence&#xD;
      due to external anal sphincter dysfunction caused by its disruption and/or weakness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 31, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in frequency of incontinence episodes</measure>
    <time_frame>12 Months</time_frame>
    <description>Urge fecal incontinence</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Urge Incontinence</condition>
  <arm_group>
    <arm_group_label>aSMDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous skeletal muscle derived cells for the treatment of urge fecal incontinence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control is the vehicle solution used for the study product</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aSMDC</intervention_name>
    <description>Autologous Muscle Derived Cells for injection into the external anal sphincter</description>
    <arm_group_label>aSMDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control is the vehicle solution used for the study product</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be at least 18 years old&#xD;
&#xD;
          -  Patients who are mentally competent and able to understand all study requirements&#xD;
&#xD;
          -  Female patients of childbearing potential willing to use appropriate methods of&#xD;
             contraception&#xD;
&#xD;
          -  Patient has symptoms of urge fecal incontinence with a disease duration of at least 6&#xD;
             months&#xD;
&#xD;
          -  Urge fecal incontinence episodes that occur more than twice a week&#xD;
&#xD;
          -  Incremental voluntary maximum squeeze pressure on anal manometry is 100mmHg or less in&#xD;
             women and 150mmHg or less in men&#xD;
&#xD;
          -  Ultrasound of the anal canal showing the overall extent of external anal sphincter&#xD;
             injury and tear of 180 degrees or less&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients for whom the investigator determines that FI has a different cause than&#xD;
             external anal sphincter dysfunction.&#xD;
&#xD;
          -  Patients with global fragmentation of the external anal sphincter as assessed by anal&#xD;
             canal ultrasound&#xD;
&#xD;
          -  Patients who underwent any anorectal surgery within 6 months before screening visit&#xD;
&#xD;
          -  Patients who underwent a total of two or more external anal sphincter-related&#xD;
             surgeries&#xD;
&#xD;
          -  Patients who currently have anal fistulas or fissures or have recurrent anal fistulas&#xD;
             or fissures&#xD;
&#xD;
          -  Patients with poorly controlled chronic constipation including obstructed defecation&#xD;
             syndrome&#xD;
&#xD;
          -  Patients with indications against a surgery under anesthesia&#xD;
&#xD;
          -  Patients with a malignant disease not in remission for 5 years or more&#xD;
&#xD;
          -  Patients who have undergone radiation therapy of the bowel and pelvis&#xD;
&#xD;
          -  Patients who have undergone chemotherapy within last 5 years prior to study enrolment&#xD;
             and/or chemotherapy related neuropathy of the bowel and pelvis&#xD;
&#xD;
          -  Patients with compromised immune system and/or rheumatic disease, and patients under&#xD;
             immunosuppressive therapy&#xD;
&#xD;
          -  Patients with a diagnosis of chronic inflammatory bowel disease&#xD;
&#xD;
          -  Patients suffering from a disease which has not been resolved within 4 weeks prior to&#xD;
             screening including fever and/or diarrhea of unknown reasons (4 weeks)&#xD;
&#xD;
          -  Patients diagnosed with human immunodeficiency virus (HIV), acute or chronic viral&#xD;
             hepatitis HCV, acute or chronic viral hepatitis HBV, active Syphilis or HTLV (tested&#xD;
             upon risk assessment by investigator)&#xD;
&#xD;
          -  Patients diagnosed with any kind of skeletal muscle disease and/or neuronal disorders&#xD;
&#xD;
          -  Patients with severe myocardial disorders, irregular pulse or a pacemaker&#xD;
&#xD;
          -  Patients with implantations of metal components in the electrical stimulation&#xD;
             treatment area&#xD;
&#xD;
          -  Patients with uncontrolled diabetes mellitus type I or II, or suffering from diabetic&#xD;
             peripheral neuropathic pain&#xD;
&#xD;
          -  Patients with clinically relevant abnormal laboratory values judged by the responsible&#xD;
             investigator as relevant for the study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melanie Amort-Achm√ºller</last_name>
    <phone>+43512573680</phone>
    <email>melanie.amort-achmueller@innovacell.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>July 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

